Skip to main content

Table 3 Drug-related nonhematologic adverse events, that occurred in ≥ 10% of patients in any treatment arm, hematologic adverse events, and biochemical abnormalities, during the DASISION trial.

From: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

 

All grade (grade 3-4), % of patients

Adverse event

Imatinib

400 mg QD

Dasatinib

100 mg QD

Nonhematologic

  

   Nausea

20 (0)

8 (0)

   Diarrhea

17 (1)

17 (< 1)

   Vomiting

10 (0)

5 (0)

   Rash

17 (1)

11 (0)

   Headache

10 (0)

12 (0)

   Fatigue

10 (0)

8 (< 1)

   Musculoskeletal pain

14 (< 1)

11 (0)

   Muscle inflammation

17 (< 1)

4 (0)

   Fluid retention

42 (1)

19 (1)

Superficial edema

36 (< 1)

9 (0)

Pleural effusion

0 (0)

10 (0)

Other

8 (< 1)

5 (1)

Hematologic

  

   Neutropenia

58 (20)

65 (21)

   Thrombocytopenia

62 (10)

70 (19)

   Anemia

84 (7)

90 (10)

Biochemical abnormalities

  

   Elevated AST

NL (1)

NL (< 1)

   Elevated ALT

NL (1)

NL (< 1)

   Elevated bilirubin

NL (0)

NL (1)

   Elevated lipase

NL (0)

NL (0)

   Hyperglycemia

NL (0)

NL (0)

   Elevated amylase

NL (0)

NL (0)

   Decreased phosphorus

NL (21)

NL (4)

  1. ALT: alanine aminotransferase; AST: aspartate aminotransferase; NL: not listed; QD: once daily.